Nurix Stock Analysis

NRIX
 Stock
  

USD 13.03  0.14  1.09%   

The current indifference towards the small price fluctuations of Nurix Therapeutics may encourage investors to take a closer look at the firm as it is trading at a share price of 13.03 on 271,700 in trading volume. The company executives did not add any value to Nurix Therapeutics investors in September. However, most investors can still diversify their portfolios with Nurix Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.05. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Nurix Therapeutics partners.
Additionally, see Correlation Analysis.
  
The Nurix Therapeutics stock analysis report makes it easy to digest most publicly released information about Nurix Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Nurix Stock analysis module also helps to analyze the Nurix Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Nurix Stock Analysis Notes

About 101.0% of the company shares are owned by institutional investors. The book value of Nurix Therapeutics was now reported as 5.92. The company recorded a loss per share of 3.05. Nurix Therapeutics had not issued any dividends in recent years. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. To find out more about Nurix Therapeutics contact the company at 415 660 5320 or learn more at https://www.nurixtx.com.

Nurix Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Nurix Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Nurix Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Nurix Therapeutics has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 38.7 M. Net Loss for the year was (154.47 M) with loss before overhead, payroll, taxes, and interest of (86.68 M).
Nurix Therapeutics currently holds about 297.28 M in cash with (136.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32.
Latest headline from finance.yahoo.com: 40 Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment DelveInsight - Yahoo Finance

Nurix Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Nurix Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nurix Therapeutics backward and forwards among themselves. Nurix Therapeutics' institutional investor refers to the entity that pools money to purchase Nurix Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Price T Rowe Associates IncCommon Shares4.6 M58.5 M
Baker Bros Advisors LpCommon Shares3.9 M49.2 M
Blackrock IncCommon Shares3.4 M42.5 M
Redmile Group LlcCommon SharesM38.1 M
Deep Track Capital LpCommon Shares2.4 M30.9 M
Wasatch Advisors IncCommon Shares2.3 M28.7 M
State Street CorpCommon Shares2.1 M26.8 M
Note, although Nurix Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nurix Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 589.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nurix Therapeutics's market, we take the total number of its shares issued and multiply it by Nurix Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (21.29) % which means that it has lost $21.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (46.46) %, meaning that it created substantial loss on money invested by shareholders. Nurix Therapeutics management efficiency ratios could be used to measure how well nurix therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of October, Nurix Therapeutics secures the Risk Adjusted Performance of 0.0502, downside deviation of 5.26, and Mean Deviation of 3.87. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nurix Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Nurix Therapeutics, which can be compared to its peers in the industry. Please verify Nurix Therapeutics information ratio and downside variance to decide if Nurix Therapeutics is priced some-what accurately, providing market reflects its recent price of 13.03 per share. Given that Nurix Therapeutics has jensen alpha of 0.3889, we recommend you to check Nurix Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Nurix Therapeutics Price Movement Analysis

Study
The minimum time period for execution of this function requires larger time horizon. Please increase the time horizon for this function. The output start index for this execution was zero with a total number of output elements of zero. The Instantaneous Trendline is a moving-average-like indicator which is formed by removing the Dominant Cycle from Nurix Therapeutics price series.
.

Nurix Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nurix Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nurix Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nurix Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Saltzman Edward C over two weeks ago via Macroaxis 
Acquisition by Saltzman Edward C of 50000 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over a month ago via Macroaxis 
Acquisition by Van Houte Hans of 120000 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over a month ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 2886 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over three months ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 68333 shares of Nurix Therapeutics subject to Rule 16b-3
Lacey David L over three months ago via Macroaxis 
Acquisition by Lacey David L of 17500 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over three months ago via Macroaxis 
Exercise or conversion by Van Houte Hans of 2886 shares of Nurix Therapeutics subject to Rule 16b-3
Van Houte Hans over six months ago via Macroaxis 
Acquisition by Van Houte Hans of 46177 shares of Nurix Therapeutics subject to Rule 16b-3
Ring Christine over six months ago via Macroaxis 
Exercise or conversion by Ring Christine of 1200 shares of Nurix Therapeutics subject to Rule 16b-3
Hansen Gwenn over six months ago via Macroaxis 
Exercise or conversion by Hansen Gwenn of 1428 shares of Nurix Therapeutics subject to Rule 16b-3
Ring Christine over six months ago via Macroaxis 
Exercise or conversion by Ring Christine of 1200 shares of Nurix Therapeutics subject to Rule 16b-3
Hansen Gwenn over six months ago via Macroaxis 
Exercise or conversion by Hansen Gwenn of 400 shares of Nurix Therapeutics subject to Rule 16b-3
Ring Christine over six months ago via Macroaxis 
Exercise or conversion by Ring Christine of 1200 shares of Nurix Therapeutics subject to Rule 16b-3

Nurix Therapeutics Predictive Daily Indicators

Nurix Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nurix Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Nurix Therapeutics Forecast Models

Nurix Therapeutics time-series forecasting models is one of many Nurix Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nurix Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Nurix Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nurix Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nurix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Nurix Therapeutics. By using and applying Nurix Stock analysis, traders can create a robust methodology for identifying Nurix entry and exit points for their positions.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.

Current Nurix Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nurix analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nurix analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
48.0Buy6Odds
Nurix Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Nurix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Nurix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Nurix Therapeutics, talking to its executives and customers, or listening to Nurix conference calls.
Nurix Analyst Advice Details

Nurix Stock Analysis Indicators

Nurix Therapeutics stock analysis indicators help investors evaluate how Nurix Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nurix Therapeutics shares will generate the highest return on investment. By understating and applying Nurix Therapeutics stock analysis, traders can identify Nurix Therapeutics position entry and exit signals to maximize returns.
Quick Ratio4.10
Fifty Two Week Low7.52
Revenue Growth61.20%
Shares Short Prior Month5.38M
Average Daily Volume Last 10 Day447.68k
Average Daily Volume In Three Month425.94k
Shares Percent Shares Out10.02%
Short Percent Of Float12.21%
Forward Price Earnings-3.27
Float Shares36.04M
Fifty Two Week High36.24
Enterprise Value To Ebitda-2.02
Fifty Day Average16.16
Two Hundred Day Average16.22
Enterprise Value To Revenue7.92
Additionally, see Correlation Analysis. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for analysis

When running Nurix Therapeutics price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Nurix Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix Therapeutics. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nurix Therapeutics is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nurix Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix Therapeutics' market value can be influenced by many factors that don't directly affect Nurix Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nurix Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Nurix Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.